Schadt Eric
Known title: Chief Executive OfficerCIK: 0001873468
Schadt Eric's purchase track record
Schadt Eric has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2022 | WGS | $192K | -38.3% | -67.8% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| WGS | ▲ Buy | Open Market | 100,000 | $192K | 5/20/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 35,899 | $78K | 4/28/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 78,812 | — | 4/25/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 29,100 | $83K | 1/28/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 78,812 | — | 1/25/2022 | View on chart |
| WGS | ▼ Sell | Tax Withholding | 5,452 | $30K | 12/1/2021 | View on chart |
| WGS | ▲ Buy | Grant | 10,727 | $65K | 12/1/2021 | View on chart |
| WGS | ▲ Buy | Option Exercise | 78,812 | — | 10/25/2021 | View on chart |
| WGS | ▼ Sell | Open Market | 33,332 | $251K | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data
GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.